Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JD Health International's Accounts Payable for the quarter that ended in Dec. 2025 was €1,602 Mil.
JD Health International's quarterly Accounts Payable
increased
from Dec. 2024 (€1,367 Mil) to Jun. 2025 (€1,641 Mil) but then
declined
from Jun. 2025 (€1,641 Mil) to Dec. 2025 (€1,602 Mil).
JD Health International's annual Accounts Payable
increased
from Dec. 2023 (€1,241 Mil) to Dec. 2024 (€1,367 Mil) and
increased
from Dec. 2024 (€1,367 Mil) to Dec. 2025 (€1,602 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JD Health International Accounts Payable Calculation
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
JD Health International (STU:8ZN) has a Accounts Payable of €1,602 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on JD Health International and its competitors.
Is JD Health International's Accounts Payable too high?
JD Health International's current Accounts Payable is €1,602 Mil. Overall, JD Health International has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JD Health International's Accounts Payable compare to competitors?
JD Health International's Accounts Payable of €1,602 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Healthcare Providers & Services company?
A good Accounts Payable depends on the Healthcare Providers & Services industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on JD Health International and its competitors. JD Health International's current Accounts Payable is €1,602 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JD Health International stock overvalued right now?
Based on GuruFocus' analysis, JD Health International (STU:8ZN) is currently considered Significantly Undervalued. The stock's GF Value™ is €6.49, compared to a current price of €4.20 — trading 35.2% below its estimated fair value. The current Accounts Payable is €1,602 Mil. JD Health International's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For JD Health International (STU:8ZN), the current Accounts Payable is €1,602 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JD Health International (STU:8ZN) Overvalued in 2026?
Based on GuruFocus' analysis, JD Health International stock appears to be undervalued.
The current stock price of €4.20 is trading 35.2% below its estimated GF Value™ of €6.49.
GuruFocus considers JD Health International to be Significantly Undervalued.
Key valuation signals for STU:8ZN:
Accounts Payable: €1,602 Mil
GF Value™: €6.49 vs. price of €4.20 (35.2% below fair value)
No single metric tells the full story. See the STU:8ZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JD Health is the largest healthcare e-commerce platform in China in terms of revenue. The company offers pharmaceutical drugs and healthcare products on its platform, both as a marketplace that connects merchants to consumers and as a first-party, or 1P, direct retailer. It also offers online consultation from real life doctors and separately partners with offline pharmacies that can provide location-based 24/7 delivery as part of an omnichannel initiative to complement its core e-commerce business. Its closest competitors are Alibaba Health and Meituan for its e-commerce business. As of Dec. 31, 2024, the platform has over 200 million active annual users and over 70,000 merchants. JD Health is 67.49% owned by its parent company, JD.com.
84GF Score
Get the complete analysis for STU:8ZN
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:8ZN has been successfully added to your 
